Osteonil 150 mg (Tablet)
1 tablet kit: ৳ 1,500.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ibandronic acid |
| Company | Albion laboratories limited |
Indications
- Treatment of osteoporosis in women (specially postmenopausal)
- Prevention of osteoporosis in women (specially postmenopausal)
- Prevention and treatment of osteoporosis in men
- Confirmed low bone mass (T-score < -2.0 SD)
- Low bone mass (T-score < -2.5 SD)
- Presence or history of osteoporotic fracture
Pharmacology
- Inhibition of bone resorption
- Prevention of experimentally induced bone destruction
- Highly potent inhibitor of osteoclastic activity
- No evidence of impaired mineralization in rats
- Specific inhibition of osteoclast activity
- Reduction of bone resorption
- Increased bone mass in young rats
- Selective action on bone tissue
Dosage & Administration
- Recommended dose: 150 mg once a month
- Tablet should be taken with plain water
- Swallowed whole with a full glass of water
- Should be taken 60 minutes before food or other medications
- Supplemental calcium or vitamin D may be required
- Instructions for missed doses
Interaction
- Interference with calcium supplements and antacids
- No interaction potential with tamoxifen or hormone replacement therapy
- Increased bioavailability with ranitidine
- No significant drug interactions
- Renal excretion only
- Similar incidence of upper gastrointestinal events with aspirin/NSAIDs
Contraindications
- Known hypersensitivity to ibandronic acid
- Uncorrected hypocalcemia
- Abnormalities of the esophagus delaying esophageal emptying
- Inability to stand or sit upright for at least 60 minutes
Side Effects
- Dyspepsia
- Nausea
- Diarrhea
- Abdominal pain
- Muscle aches
- Headaches
- Dizziness
Pregnancy & Lactation
- Not to be used during pregnancy
- No evidence of direct fetal toxicity or teratogenic effects
- Decreased number of implantation sites
- Interference with natural delivery
- Adverse effects during lactation
Precautions & Warnings
- Effective treatment of hypocalcemia before therapy
- Adequate intake of calcium and vitamin D
- Possible local irritation of upper gastrointestinal mucosa
- Caution in patients with active upper gastrointestinal problems
- Increased risk of_esophageal adverse experiences
- Possible gastric and duodenal ulcers
- Risk of osteonecrosis of the jaw (ONJ)
- No established safety and efficacy in patients less than 18 years old
Use in Special Populations
- No dosage adjustment for mild/moderate renal impairment
- Assessment necessary for severe renal impairment
- No dosage adjustment for hepatic impairment
- No dosage adjustment for elderly patients
- Safety and efficacy not established in children less than 18 years old
Overdose Effects
- No specific information available
- Possible upper gastrointestinal adverse events
- Risk of esophageal irritation
- Avoid inducing vomiting
Therapeutic Class
- Bisphosphonate preparations
Storage Conditions
- Keep below 30°C
- Away from light and moisture
- Keep out of the reach of children